首页> 外文期刊>The Indian journal of medical research >Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G < A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement
【24h】

Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G < A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement

机译:机械心脏瓣膜置换患者的细胞色素P450(CYP2C9 * 2,* 3)和维生素K环氧还原酶复合物(VKORC1 -1639G

获取原文
获取外文期刊封面目录资料

摘要

Background & objectives: Studies have demonstrated the effect of CYP2C9 (cytochrome P450) and VKORC1 (vitamin K epoxide reductase complex) gene polymorphisms on the dose of acenocoumarol. The data from India about these gene polymorphisms and their effects on acenocoumarol dose are scarce. The aim of this study was to determine the occurrence of CYP2C9*2,*3 and VKORC 1 -1639GA gene polymorphisms and to study their effects on the dose of acenocoumarol required to maintain a target International Normalized Ratio (INR) in patients with mechanical heart valve replacement. Methods: Patients from the anticoagulation clinic of a tertiary care hospital in north India were studied. The anticoagulation profile, INR (International Normalized Ratio) values and administered acenocoumarol dose were obtained from the clinical records of patients. Determination of the CYP2C9*2,*3 and VKORC1 -1639GA genotypes was done by PCR-RFLP (restriction fragment length polymorphism). Results: A total of 111 patients were studied. The genotype frequencies of CYP2C9 *1/*1,*1/*2,*1/*3 were as 0.883, 0.072, 0.036 and that of VKORC1 -1639GA for GG, AG, and AA genotypes were 0.883, 0.090, and 0.027, respectively. The percentage of patients carrying any of the variant alleles of CYP2C9 and VKORC1 in heterozygous or homozygous form was 34% among those receiving a low dose of ≤20 mg/wk while it was 13.8 per cent in those receiving 20 mg/wk (P=0.014). A tendency of lower dose requirements was seen among carriers of the studied polymorphisms. There was considerable variability in the dose requirements of patients with and without variant alleles. Interpretation & conclusions: The study findings point towards the role of CYP2C9 and VKORC1 gene polymorphisms in determining the inter-individual dose variability of acenocoumarol in the Indian patients with mechanical heart valve replacement.
机译:背景与目的:研究表明CYP2C9(细胞色素P450)和VKORC1(维生素K环氧还原酶复合物)基因多态性对乙酰香豆酚的剂量有影响。来自印度的有关这些基因多态性及其对乙酰香豆酚剂量影响的数据很少。这项研究的目的是确定CYP2C9 * 2,* 3和VKORC 1 -1639G> A基因多态性的发生,并研究其对维持目标国际标准化比率(INR)所需的乙型香豆酚剂量的影响。机械心脏瓣膜置换。方法:研究了印度北部一家三级护理医院抗凝门诊的患者。从患者的临床记录中获得抗凝曲线,INR(国际归一化比率)值和乙酰香豆酚剂量。通过PCR-RFLP(限制性片段长度多态性)确定CYP2C9 * 2,* 3和VKORC1 -1639G> A基因型。结果:共研究了111例患者。对于GG,AG和AA基因型,CYP2C9 * 1 / * 1,* 1 / * 2,* 1 / * 3的基因型频率分别为0.883、0.072、0.036和VKORC1 -1639G> A的基因型频率为0.883、0.090,和0.027。在低剂量≤20mg / wk的患者中,以杂合或纯合形式携带CYP2C9和VKORC1的任何变异等位基因的患者的百分比为34%,而在> 20 mg / wk的患者中为13.8% = 0.014)。在所研究的多态性的携带者之间发现了较低剂量需求的趋势。有和没有变异等位基因的患者的剂量要求存在很大差异。解释与结论:研究发现指出CYP2C9和VKORC1基因多态性在确定印度心脏机械换瓣患者中乙酰甲香酚个体间剂量变异性中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号